Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Gall

Showing results (351-360 of 362) with videos related to

Pageof 37
Sort By:
Iscience|August 9, 2023
Soluble prefusion-closed HIV-envelope trimers with glycan-covered basesAdam S Olia, Cheng Cheng, Tongqing Zhou, et al.
JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.
Science Translational Medicine|October 9, 2024
A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivoJohn Misasi, Ronnie R Wei, Lingshu Wang, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
The Lancet. HIV|May 23, 2025
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adultsRichard L Wu, Katherine V Houser, Martin R Gaudinski, et al.
NPJ Vaccines|September 17, 2024
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccineJoseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, et al.
Pageof 37

Showing results (351-360 of 362) with videos related to

Sort By:
Pageof 37
Iscience|August 9, 2023
Soluble prefusion-closed HIV-envelope trimers with glycan-covered basesAdam S Olia, Cheng Cheng, Tongqing Zhou, et al.
JCI Insight|April 8, 2024
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LSSeemal F Awan, Amarendra Pegu, Larisa Strom, et al.
Science Translational Medicine|October 9, 2024
A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivoJohn Misasi, Ronnie R Wei, Lingshu Wang, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
The New England Journal of Medicine|August 3, 2022
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent MalariaRichard L Wu, Azza H Idris, Nina M Berkowitz, et al.
The Lancet. HIV|May 23, 2025
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adultsRichard L Wu, Katherine V Houser, Martin R Gaudinski, et al.
NPJ Vaccines|September 17, 2024
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccineJoseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, et al.
Pageof 37